AngioDynamics, Inc. (NASDAQ:ANGO) CEO James C. Clemmer Acquires 10,000 Shares of Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CEO James C. Clemmer acquired 10,000 shares of AngioDynamics stock in a transaction dated Monday, April 8th. The stock was purchased at an average price of $6.70 per share, with a total value of $67,000.00. Following the completion of the purchase, the chief executive officer now owns 539,066 shares of the company’s stock, valued at $3,611,742.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

AngioDynamics Trading Down 6.0 %

Shares of ANGO stock opened at $6.61 on Tuesday. The stock has a 50 day moving average of $5.84 and a 200 day moving average of $6.49. The stock has a market cap of $263.41 million, a P/E ratio of -1.37 and a beta of 0.66. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $11.38.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Friday, January 5th. The medical instruments supplier reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. AngioDynamics had a negative return on equity of 3.49% and a negative net margin of 60.21%. The company had revenue of $79.07 million for the quarter, compared to analyst estimates of $81.65 million. On average, research analysts predict that AngioDynamics, Inc. will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Oppenheimer upgraded AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Friday. HC Wainwright reduced their price objective on AngioDynamics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, January 8th. Finally, Raymond James reduced their price target on AngioDynamics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, January 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.

Institutional Trading of AngioDynamics

Several institutional investors have recently bought and sold shares of ANGO. Victory Capital Management Inc. grew its holdings in AngioDynamics by 47.3% in the fourth quarter. Victory Capital Management Inc. now owns 4,261,474 shares of the medical instruments supplier’s stock valued at $58,680,000 after purchasing an additional 1,369,109 shares during the period. Millennium Management LLC grew its holdings in AngioDynamics by 121.5% in the fourth quarter. Millennium Management LLC now owns 1,953,005 shares of the medical instruments supplier’s stock valued at $26,893,000 after purchasing an additional 1,071,419 shares during the period. Armistice Capital LLC acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $6,272,000. BlackRock Inc. grew its holdings in AngioDynamics by 8.6% in the first quarter. BlackRock Inc. now owns 7,288,611 shares of the medical instruments supplier’s stock valued at $75,364,000 after purchasing an additional 574,714 shares during the period. Finally, Fund 1 Investments LLC acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $3,896,000. 89.43% of the stock is owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.